乙型肝炎核心相关抗原可分层评估HBeAg阴性不确定期患者的肝癌风险
研究基于台湾发现队列2150例和日本验证队列1312例HBeAg阴性、未治疗、无肝硬化的慢性乙型肝炎患者,探讨不确定期患者的肝细胞癌风险及血清HBcrAg水平的风险分层价值。按HBcrAg 10000 U/mL分层,低水平组与高水平组10年肝细胞癌累积发生率分别为0.51%和5.33%,风险比为4.47(95%CI:2.62-7.63),该切点在独立日本队列中得到验证。
要点
- 台湾队列中46%(990例)HBeAg阴性患者基线为不确定期,其肝癌风险介于非活动期与免疫活动期之间。
- HBcrAg 10000 U/mL可分层肝癌风险:低水平组10年累积发生率0.51% vs 高水平组5.33%,HR 4.47(95%CI:2.62-7.63)。
- 联合ALT、HBV DNA和HBcrAg水平可将HBeAg阴性患者简单重分类为高风险和低风险组。
核心结论
- 血清HBcrAg水平10000 U/mL可对HBeAg阴性不确定期患者进行肝癌风险分层,有助于优化其临床管理。
研究设计与样本
- 构建两个回顾性队列,纳入HBeAg阴性、未治疗、无肝硬化的慢性乙型肝炎患者。
- 台湾发现队列N=2150,平均随访15.88年;日本验证队列N=1312,平均随访12.07年。
- 主要终点为肝细胞癌发生。
主要发现
- 按美国肝病研究学会指南,台湾队列中990例(46%)HBeAg阴性患者基线为不确定期。
- 不确定期患者肝癌风险介于非活动期和免疫活动期患者之间,且风险多样。
- 按HBcrAg 10000 U/mL分层,低水平组10年肝癌累积发生率为0.51%,高水平组为5.33%,风险比为4.47(95%CI:2.62-7.63)。
- 该切点在多个亚组分析及独立日本队列中均验证可分层肝癌风险。
- 在两个队列中,联合ALT、HBV DNA和HBcrAg水平可将HBeAg阴性慢性乙型肝炎患者重分类为高风险和低风险组。
临床怎么用
- 血清HBcrAg水平10000 U/mL可用于HBeAg阴性不确定期患者的肝癌风险分层。
- 联合ALT、HBV DNA和HBcrAg水平可将HBeAg阴性患者重分类为高风险和低风险组,有助于优化临床管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Many patients with chronic hepatitis B (CHB) are classified as indeterminate patients because they fall outside the defined CHB phases. We aimed to explore hepatocellular carcinoma (HCC) risk in hepatitis B e antigen (HBeAg)-negative patients with indeterminate phase and investigated whether the risk could be stratified by serum levels of hepatitis B core-related antigen (HBcrAg). METHODS: Two retrospective cohorts enrolling HBeAg-negative, treatment-naïve CHB patients without cirrhosis were constructed (N = 2,150 in Taiwanese discovery cohort and N = 1,312 in Japanese validation cohort with a mean follow-up period of 15.88 and 12.07 years, respectively). The primary end point was HCC development. RESULTS: According to the American Association for the Study of Liver Disease guidelines, 990 (46%) HBeAg-negative patients had indeterminate CHB phase at baseline in the Taiwanese cohort. Compared with the patients with inactive CHB and those with immune-active CHB, the indeterminate patients exhibited intermediate but diverse risk of HCC. When HCC risk was stratified by a HBcrAg level of 10,000 U/mL, 10-year HCC cumulative incidence was 0.51% and 5.33% for low HBcrAg and high HBcrAg groups, respectively, with a hazard ratio of 4.47 (95% confidence interval: 2.62-7.63). This cutoff was validated to stratify HCC risk not only in different subgroup analyses but also in an independent Japanese cohort. Finally, the overall HBeAg-negative CHB patients could be simply reclassified into high-risk and low-risk groups by combining ALT, hepatitis B virus DNA, and HBcrAg levels in both cohorts. DISCUSSION: Serum HBcrAg level of 10,000 U/mL stratifies HCC risk in HBeAg-negative patients with indeterminate phase, which is useful for optimizing their clinical management.
引用
- Tseng TC, Hosaka T, Liu CJ, et al. Hepatitis B Core-Related Antigen Stratifies the Risk of Liver Cancer in HBeAg-Negative Patients With Indeterminate Phase. Am J Gastroenterol. 2022. PMID: 35191399. doi:10.14309/ajg.0000000000001691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。